USANA Health Sciences Finishes Strong 2020 with 14.5% Fourth Quarter Net Sales Growth and 32.6% Diluted EPS Growth
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
USANA Health Sciences Inc. (USNA) PT Raised to $126 at Roth Capital
February 10, 2021 7:12 AM ESTRoth Capital analyst David Bain raised the price target on USANA Health Sciences Inc. (NYSE: USNA) to $126.00 (from $107.00) while maintaining a Buy rating.
The analyst comments "Following a 7%/~24% revenue/EBITDA beat versus consensus, we raise our CY21/CY22 estimates and target price.... More
USANA Health Sciences (USNA) Tops Q4 EPS by 44c, Offers Guidance
February 9, 2021 4:20 PM ESTUSANA Health Sciences (NYSE: USNA) reported Q4 EPS of $1.87, $0.44 better than the analyst estimate of $1.43. Revenue for the quarter came in at $310.5 million versus the consensus estimate of $291.54 million.
GUIDANCE:
USANA Health Sciences sees FY2021 EPS of $6.00-$6.45, versus the... More
